home > news > detailed info

Pharmaceutical and Medical Industry Increasingly Demands Automated Testing Solutions


After the manufacturing processes in pharmaceutical and medical industries reached a high level of automation in recent years, manufacturers are more committed to automating their testing processes as well. Production-related tests as well as tests for product release are to be largely automated. In addition to higher specimen throughput, an increase in reproducibility through the elimination of operator influence is a main objective for manufacturers. Zwick Roell offers various levels of automation for testing syringes, insulin pens, and auto injectors.

The market for pre-filled syringes is growing steadily. This development is reflected in the growth of biological and complex active ingredients as well as in the increasing requirements of patients and nursing staff. Experts estimate that this market will double to approximately 6 million units by 2024.* The increasing production numbers also affect quality control. The pharmaceutical industry is increasingly looking for reliable testing solutions that are also economical.

Zwick Roell offers a special test fixture in conjunction with a semi-automatic feeding system for testing such pre-filled syringes. This test fixture is used to determine the breakaway force and glide force of syringes, syringe cartridges, and similar dosimeters. The test is based on the following standards: DIN EN ISO 7886 -1, DIN EN ISO 11499 and ISO 11040-4. The breakaway force and glide force are important parameters used to select the most suitable syringe. These forces may not exceed or fall below certain limits to ensure that a safe drug dose is administered. In addition to the friction in the syringe, the forces are influenced by the viscosity of the drug and the size of the cannula. To reducer operator influence (MSA 3/Gauge R&R Type 3) when simultaneously increasing the clock frequency, the test fixture can be combined with a semi-automatic feeding system. This rotation magazine holds up to 15 syringes and isversatile since the fixture can be used for various syringe diameters. By using a second rotation magazine on the the same machine, the cap removal force can also be determined before the glide force.

The test is controlled and evaluated via the testXpert III software, enabling all requirements of the expanded Traceability to be met according to FDA 21Part 11. The testing system can also be equipped with a precision scale that can be used to determine the escaping drug amounts in addition to the breakaway/glide force. To support the validation of the testing machine, Zwick can perform a complete qualification (DQ/IQ/OQ).
phone +49 7305 100
email August-Nagel-Strasse 11, 89079, ULM, Germany
Print this page
Send to a friend
News and Press Releases

2019 Pharmapack Awards

Pharmapack Europe have announced entries for the 2019 Pharmapack Awards are now open across both the ‘Exhibitor Innovation’ and ‘Health Products’ categories with a closing date of 30th November 2018. The Health Products category will include two winners with one for Patient-Centric Design – which is launched in partnership with HCPC Europe (Healthcare Compliance Packaging Council of Europe) – and a second introduced alongside Adelphe for Eco-design in health packaging and drug delivery devices. Pharmapack Europe have also announced that they’re accepting applications for the start-up hub which provides young start-up companies servicing the pharma industry with the benefit of valuable networking and learning opportunities at half the price of a regular stand.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement